368 results on '"Diverio, D"'
Search Results
2. BCR-ABL1 GENE TRANSLOCATION MONITORING IN LONG-TERM SURVIVING CHRONIC MYELOID LEUKEMIA PATIENTS AFTER MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION: PH-P098
3. PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis
4. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes
5. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
6. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML
7. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells
8. Characterization of a recurrent translocation t(2;3)(p15–22;q26) occurring in acute myeloid leukaemia
9. Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia
10. Interleukin-3 receptor in acute leukemia
11. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease
12. Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis
13. C-fms expression correlates with monocytic differentiation in PML-RARα+ acute promyelocytic leukemia
14. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
15. Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia
16. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’?
17. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts
18. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients
19. HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome
20. Persistence of BCR-ABL1 gene signal in 10-year survivors of myeloablative allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: P722
21. Preliminary experience in external quality control of RT-PCR PML-RARα detection in promyelocytic leukemia
22. Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML1 5 trial: 162
23. Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status
24. Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL): 116
25. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results
26. Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukaemia
27. DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) IN APL BY "REAL-TIME" RT-PCR: ANALYSIS OF CASES ENTERED INTO THE MRC ATRA TRIAL
28. THERAPY OF MINIMAL DISEASE RECURRENCE IN ACUTE PROMYELOCYTIC LEUKEMIA
29. CLINICAL AND BIOLOGICAL RELEVANCE OF IMMUNOPHENOTYPE IN ACUTE PROMYELOCYTIC LEUKEMIA: A STUDY OF 196 CASES
30. HLA CLASS I AND SUSCEPTIBILITY TO ACUTE PROMYELOCYTIC LEUKEMIA
31. Managing Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. The Italian Experience
32. Erratum: Characterization of a recurrent translocation t(2;3)(p15–22;q26) occurring in acute myeloid leukemia
33. LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION
34. Primary Trombocythemia in Children and Adolescents Includes Different Subtypes Compared to Adult Essential Thrombocythemia
35. Discontinuation of Imatinib (IM) in pediatrica chronic myeloid leukemia (CML) patients with sustained complete molecular remission (CMR)
36. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
37. GIMEMA AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials
38. ITALIAN STANDARDIZATION OF BCR-ABL RQ-PCR AND QUALITY CONTROL METHODS: AN OVERVIEW OF FIRST 4 YEARS RESULTS
39. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
40. Imatinib Mesylate induces high complete cytogenetic and major molecular response rates in children and adolescents with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase
41. ACCURACY AND PRECISION OF RESULTS AFTER IMPLEMENTATION OF INTERNATIONAL SCALE TO EVALUATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA PATIENTS COORDINATED ON BEHALF OF GIMEMA-CML WP
42. FLT3-ITD ABNORMALITIES AND COMORBIDITIES AS INDEPENDENT PROGNOSTIC INDICATORS OF SURVIVAL IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS
43. IMATINIB TREATMENT IN ELDERLY PATIENTS (>65 YEARS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE
44. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent geneticabnormalities: a comparative analysis of 2562 patients with acute myeloidleukemia
45. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
46. Molecular monitoring in core binding factor aml patients undergoing an autologous peripheral blood stem cell transplantation
47. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloidleukemia
48. Epigenetic deregulation of microRNA-223 in Myeloid Leukemogenesis
49. Phenotypic and molecular features of acute promyelocytic leukemia patients developing retinoic acid syndrome
50. FLT3 positive acute myeloid leukemia: A single center experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.